Table 2.
Risk of ischaemic stroke associated with ECG-LVH and prolonged QTa
| ECG-LVH | Prolonged QTa | Incidence rate per 1000 person-years | Model 1a HR (95% CI) | Model 2b HR (95% CI) | Model 3c HR (95% CI) |
|---|---|---|---|---|---|
| Absent | Absent | 3.7 (3.4–4.0) | Referent | Referent | Referent |
| Present | Absent | 6.2 (5.1–7.5) | 1.49 (1.20–1.85) | 1.42 (1.14–1.77) | 1.41 (1.13–1.76) |
| Absent | Present | 9.3 (6.8–12.8) | 1.76 (1.26–2.45) | 1.46 (1.05–2.05) | 1.43 (1.02–2.00) |
| Present | Present | 13.8 (7.8–24.2) | 2.26 (1.27–4.01) | 1.88 (1.06–3.35) | 1.86 (1.04–3.31) |
CI, confidence interval; ECG-LVH, electrocardiographic left ventricular hypertrophy; HR, hazard ratio; QTa, heart rate-adjusted QT interval.
aModel 1, adjusted for age, sex, race, and age × race.
bModel 2, adjusted for Model 1 covariates plus systolic blood pressure, antihypertensive medications, current smoking, diabetes, body mass index, atrial fibrillation, and prevalent coronary heart disease.
cModel 3, adjusted for Model 2 covariates plus QT prolonging medications, statin use, warfarin use, and aspirin use.